Author:
Dr Takashi Umeyama (JP)
Abstract:
Objectives: Cunninghamella bertholletiae poses a severe threat to immunocompromised patients, emerging as one of the most virulent causative agents of mucormycosis. Additionally, it is identified as a multidrug-resistant filamentous fungus, showing low susceptibility to three antifungal agent classes. With escalating interest in its genetic foundation, mechanisms of action, and diagnostic challenges, our study’s pivotal objective is to delve into factors tied to drug resistance via whole-genome analysis of C. bertholletiae. We endeavor to elucidate these genomic nuances, laying the foundation for improved therapeutics against infections triggered by this pathogen and charting a course for cutting-edge diagnostic and therapeutic modalities.
Methods: We gently extracted genomic DNA from 11 clinical isolates of C. bertholletiae for long-read sequencing. Sequence data was then acquired using the MinION nanopore sequencer—a state-of-the-art, portable long-read sequencer. Subsequent genome assembly employed Flye, distinguished for its exceptional sequence assembly precision. Post-assembly, genes were predicted and annotated with Funannotate, a robust tool tailored for fungal genome annotation.
Results: The genome assembly of 11 clinical isolates resulted in an average of 14 contigs with a genome size of approximately 31 Mb. Gene prediction revealed roughly 9,400 open reading frames (ORFs) in each genome. These significant findings provide a comprehensive genomic framework and a starting point for detailed studies of drug resistance mechanisms and virulence determinants.
Conclusions: Our genome annotation insights will investigate genes pivotal for drug resistance and heightened virulence. We are driven by an overarching vision to morph these genomic revelations into tangible clinical solutions, spurring the introduction of innovative therapeutic and diagnostic instruments. Our endeavor targets augmenting clinical interventions against C. bertholletiae infections, propelling us toward a future with diminished threats from such ailments. Our dedication lies in deciphering the genomic essence of this formidable pathogen, ushering in a new wave of therapeutic and diagnostic breakthroughs against its challenges.
Abstract Number: 48
Conference Year: 2024
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Xiao Liua,b,c,d,e, Zhe Wana,b,c,d, Ruoyu Lia,b,c,d*, Yinggai Songa,b,c,d*
2024
29
n/a
-
v
Dr Paschalis Vergidis (UK)
2024
27
n/a
-
v
Deepa Nanayakkara (US)
2024
25
n/a
-
v
Yiyou Gu,1 Teclegiorgis Gebremariam,1 Sounds Alkhazraji1 Robina Aerts2,3 Katrien Lagrou3,4 Martin Hoenigl5 Ashraf S. Ibrahim.1,6
2024
23
n/a
-
v
Professor Immaculata Xess (IN)
2024
22
n/a
-
v
Temitope V. Fapohunda1, Olufemi T. Ojo 1,2, Ibrahim O. Odulate3, Abiola. A. Omolayole1, Olufunke O. Adeyeye1,2, Emmanuel O. bandele1
2024
21
n/a